ATHA — Athira Pharma Income Statement
0.000.00%
Last trade - 00:00- $15.26m
- -$9.96m
- 23
- 49
- 63
- 41
Annual income statement for Athira Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 19.8 | 64 | 104 | 125 | 101 |
| Operating Profit | -19.8 | -64 | -104 | -125 | -101 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -20 | -54.9 | -95.6 | -118 | -96.9 |
| Net Income After Taxes | -20 | -54.9 | -95.6 | -118 | -96.9 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -20 | -54.9 | -95.6 | -118 | -96.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -20 | -54.9 | -95.6 | -118 | -96.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -6.2 | -14.9 | -22.7 | -31.4 | -24.1 |